- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07561359
12-Week Strength and Functional Exercise Program for Hereditary Spastic Paraplegia Trial (HSPMOVE) (HSPMOVE)
12-Week Strength and Functional Exercise Protocol for Treating Motor Symptoms in Individuals With Hereditary Spastic Paraplegia: Adaptive Randomized Crossover Clinical Trial
This study aims to evaluate whether a 12-week program of strength and functional exercises can improve movement and daily function in people with Hereditary Spastic Paraplegia (HSP). Participants will take part in supervised exercise sessions twice a week, delivered by videoconference, with guidance from a physiotherapist. The exercises will be tailored to each participant's abilities and goals and will focus on improving muscle strength, balance, and walking.
The study is a randomized crossover trial, meaning that all participants will experience both the exercise program and a comparison period without the intervention.
Eligible participants are individuals aged 16 to 70 years with a clinical or genetically confirmed diagnosis of HSP, who are able to walk independently (with or without assistive devices) and have stable treatment for spasticity.
Researchers will measure changes in walking ability, balance, muscle strength, and quality of life using clinical scales and functional tests. These include walking tests, mobility assessments, and questionnaires about daily activities and confidence in movement. To reduce bias, outcome assessments will be performed by an evaluator who is blinded to the participants' group allocation.
The results of this study will help determine whether a structured exercise program is safe, feasible, and effective for improving motor symptoms in people with HSP, and may support its use as part of routine care.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-003
- Centro de Pesquisa Clínica do Hospital de Clínicas de Porto Alegre
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Diagnosis of hereditary spastic paraplegia confirmed by genetic testing or clinical diagnosis with a positive family history
- Age between 16 and 70 years
- Independent ambulation, with or without assistive devices
- Access to an electronic device (smartphone, tablet, or computer) with camera and internet connection
- Stable therapeutic regimen for spasticity management (pharmacological and/or physiotherapy) for at least 6 months prior to enrollment
Exclusion Criteria:
- Presence of other neurological or systemic conditions causing additional motor impairment or musculoskeletal injury limiting movement
- Inability to perform performance outcomes even with assistive devices
- Planned or ongoing botulinum toxin injections or surgical interventions for spasticity reduction during the 12-week intervention period
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Individualized Functional and Strength Exercise Intervention
Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist.
|
Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist.
Exercises are tailored according to Goal Attainment Scaling (GAS) and baseline physical activity level.
The program consists of two sessions per week and follows key training principles (individuality, overload, adaptation, specificity, continuity, reversibility, and variability) with progressive loading.
The intervention focuses on improving lower limb strength and functional mobility, particularly gait, and includes balance and gait training.
Sessions are scheduled with 2-3 day intervals.
Each exercise includes 1-3 sets of 8-15 repetitions, with 30-60 seconds rest between sets.
Training intensity ranges from 40-60% of maximal strength for sedentary participants and 50-70% for physically active participants.
|
|
간섭 없음: No Intervention
No individualized prescription or real-time supervision will be provided during this phase.
They will receive printed educational materials containing general guidance on performing strength and functional exercises.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Spastic Paraplegia Rating Scale (SPRS)
기간: Baseline, 12 and 24 weeks
|
Clinician-reported outcome used to assess disease severity in hereditary spastic paraplegia (HSP).
It consists of 13 items evaluating gait, lower limb strength and spasticity, joint contractures, pain, and bladder and bowel function.
Total scores range from 0 to 52, with higher scores indicating greater disease severity.
|
Baseline, 12 and 24 weeks
|
|
Timed Up and Go Test (TUG) - maximum walking speed
기간: Baseline, 12 and 24 weeks
|
Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at maximum walking speed.
The time to complete the task is recorded.
|
Baseline, 12 and 24 weeks
|
|
Goal Attainment Scaling (GAS)
기간: Baseline, 12 and 24 weeks
|
individualized patient reported outcome measure used to assess the extent to which patient-specific goals are achieved during the intervention.
Each participant will define four main individualized goals at baseline.
Goals and expected levels of performance are defined individually for each participant and scored on a 5-point scale ranging from -2 to +2.
A score of 0 represents the expected level of achievement, positive scores (+1, +2) indicate better-than-expected outcomes, and negative scores (-1, -2) indicate less-than-expected outcomes.
|
Baseline, 12 and 24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
10-Meter Walk Test (10MWT) - self-selected walking speed
기간: Baseline, 12 and 24 weeks
|
Performance outcome in which participants will walk at a comfortable, self-selected pace over a 10-meter distance.
A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone.
Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.
|
Baseline, 12 and 24 weeks
|
|
10-Meter Walk Test (10MWT) - maximum walking speed
기간: Baseline, 12 and 24 weeks
|
Performance outcome in which participants will walk at maximum walking speed over a 10-meter distance.
A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone.
Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.
|
Baseline, 12 and 24 weeks
|
|
Timed Up and Go (TUG) - self-selected walking speed
기간: Baseline, 12 and 24 weeks
|
Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at at a comfortable, self-selected pace .
The time to complete the task is recorded.
|
Baseline, 12 and 24 weeks
|
|
Falls Efficacy scale - International (Brazilian Portuguese)
기간: Baseline, 12 and 24 weeks
|
Patient-reported outcome used to assess concern about falling during daily activities in community-dwelling individuals.
It consists of 16 items covering functional and participation activities (e.g., sitting/standing from a chair, climbing stairs).
Each item is scored from 1 (not at all concerned) to 4 (very concerned), with total scores ranging from 16 to 64.
Higher scores indicate greater concern about falling.
|
Baseline, 12 and 24 weeks
|
|
36-Item Short Form Health Survey (SF-36) - Brazillian Portuguese
기간: Baseline, 12 and 24 weeks
|
Generic, patient-reported outcome of health-related quality of life.
It consists of 36 items covering multiple domains, including physical functioning, role limitations due to physical health, pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health.
Scores range from 0 to 100, with higher scores indicating better overall health status.
|
Baseline, 12 and 24 weeks
|
|
Medical Research Council (MRC) Muscle Strength Scale
기간: Baseline, 12 and 24 weeks
|
Clinician-reported outcome of muscle strength, graded from 0 (no contraction) to 5 (normal strength).
Lower limb muscle groups assessed include hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors.
|
Baseline, 12 and 24 weeks
|
|
Modified Ashworth Scale (MAS)
기간: Baseline, 12 and 24 weeks
|
Clinician-reported outcome used to assess resistance to passive movement and muscle tone.
It is scored on a 5-point scale from 0 (normal muscle tone) to 4 (rigid in flexion or extension).
In this study, it will be applied to the hip adductor and knee flexor muscles to assess lower limb spasticity.
|
Baseline, 12 and 24 weeks
|
|
Patient Global Impression of Change (PGI-C)
기간: Baseline, 12 and 24 weeks
|
Patient-reported outcome measuring perceived overall improvement or worsening following the intervention.
It is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), capturing the patient's global assessment of change.
|
Baseline, 12 and 24 weeks
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Handheld Dynamometry (microFET2)
기간: Baseline, 12 and 24 weeks
|
Digital health technology in which muscle strength will be assessed using a handheld dynamometer (microFET2) to measure peak force output in lower limb muscle groups including hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors.
This provides an objective, quantitative measure of muscle strength (expressed in kgf) for comparison with clinical scales.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Timed Up and Go test
기간: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Sit-to-stand, turning, and stand-to-sit times in seconds (1 decimal) will be recorded during and Timed Up and Go (TUG) test at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Cadence
기간: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Cadence in steps/min will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Elevation Midswing, Lateral Step Variability, Circumduction
기간: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Elevation Midswing, Lateral Step Variability, Circumduction in cm will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Gait Cycle Duration, Step Duration
기간: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Gait Cycle Duration and Step Duration in seconds will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Gait Speed
기간: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Gait Speed in m/s will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Stride Length
기간: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Stride Length in meters will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM)
기간: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM) in ° degrees will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Double Support, Single Limb Support, Stance, Swing, Terminal Double Support
기간: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Double Support, Single Limb Support, Stance, Swing, Terminal Double Support in Gait Cycle Time (%) will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2023-0040
- CAAE: 67528023.6.0000.5327 (기타 식별자: CEP-HCPA)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .